KBC Group NV cut its position in Quest Diagnostics Inc (NYSE:DGX) by 54.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 95,330 shares of the medical research company’s stock after selling 115,147 shares during the period. KBC Group NV’s holdings in Quest Diagnostics were worth $9,389,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the business. Swiss National Bank boosted its position in Quest Diagnostics by 0.5% in the fourth quarter. Swiss National Bank now owns 575,030 shares of the medical research company’s stock valued at $56,635,000 after buying an additional 2,900 shares in the last quarter. Cognios Capital LLC boosted its position in Quest Diagnostics by 4.5% in the fourth quarter. Cognios Capital LLC now owns 25,504 shares of the medical research company’s stock valued at $2,511,000 after buying an additional 1,096 shares in the last quarter. Teacher Retirement System of Texas lifted its position in shares of Quest Diagnostics by 11.9% during the fourth quarter. Teacher Retirement System of Texas now owns 226,717 shares of the medical research company’s stock worth $22,329,000 after purchasing an additional 24,075 shares in the last quarter. ING Groep NV lifted its position in shares of Quest Diagnostics by 170.1% during the fourth quarter. ING Groep NV now owns 12,960 shares of the medical research company’s stock worth $1,276,000 after purchasing an additional 8,162 shares in the last quarter. Finally, Crossmark Global Holdings Inc. lifted its position in shares of Quest Diagnostics by 1.3% during the fourth quarter. Crossmark Global Holdings Inc. now owns 120,326 shares of the medical research company’s stock worth $11,851,000 after purchasing an additional 1,497 shares in the last quarter. Hedge funds and other institutional investors own 90.22% of the company’s stock.

In other Quest Diagnostics news, Chairman Stephen H. Rusckowski sold 106,840 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $107.00, for a total value of $11,431,880.00. Following the completion of the sale, the chairman now owns 272,956 shares of the company’s stock, valued at $29,206,292. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP J. E. Davis sold 63,880 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $98.68, for a total transaction of $6,303,678.40. Following the completion of the sale, the executive vice president now directly owns 101,423 shares of the company’s stock, valued at approximately $10,008,421.64. The disclosure for this sale can be found here. Over the last three months, insiders have sold 192,014 shares of company stock valued at $19,950,134. 1.75% of the stock is currently owned by insiders.

Shares of Quest Diagnostics Inc (DGX) opened at $101.51 on Thursday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.15 and a current ratio of 1.24. The firm has a market cap of $13,819.40, a P/E ratio of 17.94, a P/E/G ratio of 1.82 and a beta of 0.67. Quest Diagnostics Inc has a 12 month low of $90.10 and a 12 month high of $112.96.

Quest Diagnostics (NYSE:DGX) last posted its quarterly earnings results on Thursday, February 1st. The medical research company reported $1.40 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.37 by $0.03. The business had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.93 billion. Quest Diagnostics had a net margin of 10.00% and a return on equity of 15.41%. Quest Diagnostics’s revenue for the quarter was up 4.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.31 earnings per share. analysts predict that Quest Diagnostics Inc will post 6.59 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 18th. Investors of record on Wednesday, April 4th will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.97%. This is an increase from Quest Diagnostics’s previous quarterly dividend of $0.45. The ex-dividend date of this dividend is Tuesday, April 3rd. Quest Diagnostics’s payout ratio is 32.73%.

A number of brokerages have recently issued reports on DGX. Zacks Investment Research upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating and set a $115.00 target price on the stock in a research report on Tuesday, February 6th. Piper Jaffray Companies reiterated a “hold” rating and set a $110.00 target price on shares of Quest Diagnostics in a research report on Thursday, February 1st. Credit Suisse Group upgraded shares of Quest Diagnostics from a “neutral” rating to an “outperform” rating and set a $107.00 target price on the stock in a research report on Tuesday. Mizuho set a $103.00 target price on shares of Quest Diagnostics and gave the stock a “buy” rating in a research report on Thursday, October 19th. Finally, Goldman Sachs Group began coverage on shares of Quest Diagnostics in a research report on Monday, January 29th. They set a “buy” rating and a $117.00 target price on the stock. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and nine have assigned a buy rating to the company’s stock. Quest Diagnostics presently has a consensus rating of “Hold” and an average target price of $107.40.

TRADEMARK VIOLATION NOTICE: This article was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://theolympiareport.com/2018/02/15/quest-diagnostics-inc-dgx-holdings-reduced-by-kbc-group-nv.html.

About Quest Diagnostics

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Inc (NYSE:DGX).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.